Cosciens Biopharma(TSX) AEZS

Current PriceN/A

Market CapN/A

Since IPO (1995)-100%

5 Year-97%

1 Year-52%

1 Month-8%

Cosciens Biopharma last closing stock price
Metric	Price	Date
Last close	CAD 7.70	2026-07-24

Cosciens Biopharma stock price return by period
Period	Price return	Price at period start	Period start date
1 week	-3.75%	CAD 8.00	2026-07-17
1 month	-8.33%	CAD 8.40	2026-06-24
3 month	-4.94%	CAD 8.10	2026-04-24
Year to date	-9.62%	CAD 8.52	2025-12-31
1 year	-51.57%	CAD 15.90	2025-07-24
3 year	-84.27%	CAD 48.96	2023-07-25
5 year	-97.08%	CAD 264.00	2021-07-23
Since inception	-100%	CAD 420,810.13	1995-12-19

Cosciens Biopharma Financials at a Glance

Market Cap

N/A

Revenue (TTM)

$2.47M

Net Income (TTM)

-$5.24M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

Aug 13, 2024

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

Aug 13, 2024

AEZS News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Cosciens Biopharma

COSCIENS Biopharma Inc. is a life science company focused on developing and commercializing products for the cosmeceutical, nutraceutical, and pharmaceutical markets. The company operates through its Active Ingredient and Pharmaceutical segments, offering innovative solutions to enhance health and wellness.

Products and Services

Active ingredients like oat beta glucan for health and wellness
Macrilen/Ghryvelin, a growth hormone secretagogue
Oat oil and peptides for cosmeceutical applications

Growth Outlook

Recent quarterly revenue of CAD 1.86 million shows a positive trend
Strong market demand for cosmeceutical products supports growth potential
Strategic partnerships enhance distribution capabilities and market reach

Financial Highlights

Trailing twelve months (TTM) revenue of CAD 7.5 million indicates steady performance
Current ratio of 5.57 suggests strong liquidity position
Cash reserves of CAD 5 million provide a buffer for operational needs

COSCIENS Biopharma Inc. has positioned itself in a growing market with a diverse product portfolio. The recent quarterly revenue reflects a positive trajectory, indicating potential for future growth. The company's strong liquidity, as evidenced by a current ratio of 5.57, allows for flexibility in operations and investment in new opportunities. With strategic partnerships in place, COSCIENS is well-equipped to expand its market presence and capitalize on the increasing demand for health and wellness products. The focus on innovative ingredients and formulations further enhances its competitive edge in the pharmaceutical and cosmeceutical sectors.

AI Generated • Jul 4, 2026

Industry

Biotechnology

Sector

Health Care

Employees

CEO

Peter Harry Puccetti, CFA

Website

www.cosciensbio.com

Headquarters

Summerville, SC 29486, US

AEZS Financials

Key Financial Metrics (TTM)

Gross Margin

37.98%

Operating Margin

-99.15%

Net Income Margin

-92.11%

Return on Equity

-92.59%

Return on Capital

-83.42%

Return on Assets

-38.42%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/A

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$865.00K

Operating Income

-$20.81M

EBITDA

-$12.25M

Operating Cash Flow

-$14.44M

Capital Expenditure

-$176.00K

Free Cash Flow

-$14.62M

Cash & ST Invst.

$27.80M

Total Debt

$1.69M

Cosciens Biopharma Performance Analysis

Cosciens Biopharma annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 7,342,454	11.3%
2023	2023-12-31	USD 9,640,814	31.3%
2024	2024-12-31	USD 13,133,822	36.2%
2025	2025-12-31	USD 10,476,870	-20.2%

Cosciens Biopharma sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2023-09-30	-99.9%
Q4	2023-12-31	3933.3%
Q1	2024-03-31	-96.7%
Q2	2024-06-30	58325.0%

Cosciens Biopharma annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -73.12	167.0%
2023	2023-12-31	USD -30.56	-58.2%
2024	2024-12-31	USD -24.37	-20.2%
2025	2025-12-31	USD -13.72	-43.7%

Cosciens Biopharma sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2023-09-30	40.4%
Q4	2023-12-31	-267.7%
Q1	2024-03-31	44.7%
Q2	2024-06-30	25.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q2 2024YOY CHG

Revenue

$2.34M

+4.1%

Gross Profit

$819.00K

-61.1%

Gross Margin

35.04%

N/A

Market Cap

N/A

Market Cap/Employee

N/A

Employees

N/A

Net Income

-$1.42M

+43.5%

EBITDA

-$3.27M

-361.1%

Quarterly Fundamentals

Name

Q2 2024YOY CHG

Total Cash

$27.80M

-34.1%

Total Debt

$1.69M

+633.5%

Accounts Receivable

$1.36M

+9.5%

Inventory

$3.06M

+3184.9%

Long Term Debt

$1.28M

-58.7%

Short Term Debt

$407.00K

-30.2%

Return on Assets

-38.42%

N/A

Return on Invested Capital

-45.42%

N/A

Free Cash Flow

-$1.55M

+64.0%

Operating Cash Flow

-$1.39M

+67.6%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

THNK.VThink Research Corporation

THNK.VThink Research CorporationCA$0.32+1.61%

IGX.TOIntelGenx Technologies Corp.

IGX.TOIntelGenx Technologies Corp.CA$0.24+17.07%

IMV.TOIMV Inc.

IMV.TOIMV Inc.CA$1.12+0.00%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$7.42-0.04%

ONDSOndas

ONDSOndas$7.80-0.02%

SOFISoFi Technologies

SOFISoFi Technologies$16.46-0.01%

TAT&T

TAT&T$24.13+0.05%

AALAmerican Airlines Group

AALAmerican Airlines Group$14.48+0.07%

CLFCleveland-Cliffs

CLFCleveland-Cliffs$11.93+0.09%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$64.00-0.03%

Questions About AEZS

What is the current price of Cosciens Biopharma?

Cosciens Biopharma is trading at N/A per share.

What is the 52-week range for Cosciens Biopharma?

Over the past 52 weeks, Cosciens Biopharma has traded between N/A and N/A.

How much debt does Cosciens Biopharma have?

As of the most recent reporting period, Cosciens Biopharma reported total debt of $2.82M.

How much cash does Cosciens Biopharma have on hand?

Cosciens Biopharma reported $6.98M in cash and cash equivalents in its most recent financial results.

What is Cosciens Biopharma’s dividend yield?

Cosciens Biopharma does not currently have a dividend yield.

Cosciens Biopharma(TSX) AEZS

Cosciens Biopharma Financials at a Glance

AEZS News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Cosciens Biopharma

AEZS Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Cosciens Biopharma Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About AEZS

What is the current price of Cosciens Biopharma?

What is the 52-week range for Cosciens Biopharma?

How much debt does Cosciens Biopharma have?

How much cash does Cosciens Biopharma have on hand?

What is Cosciens Biopharma’s dividend yield?

Premium Investing Services